Marc Dunoyer (AstraZeneca via YouTube)
On the back of PhIII success, AstraZeneca lays out the red carpet for rare disease drug Alexion paid $855M for
When Ludwig Hantson gambled $855 million to buy out Wilson Therapeutics back in 2018, the CEO framed it as the first step of rebuilding the pipeline at Alexion and branching out beyond the complement franchise anchored by Soliris and Ultomiris.
Three and a half years later, it appears to be paying off — for what is now AstraZeneca’s rare disease unit following a $39 billion buyout. It’s a win that comes just days after AstraZeneca conceded a setback in another Phase III program testing Ultomiris, the next-gen long-acting C5 drug, against ALS.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
